Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
CEVEC Pharmaceuticals
About
CEVEC Pharmaceuticals develops therapeutic proteins and monoclonal antibodies with human glycosylation patterns.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $5.40M
- Industries
- Biopharma,Biotechnology,Health Care
- Founded date
- Jan 1, 2003
- Number Of Employee
- 11 - 50
- Operating Status
- Active
CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 25, 2011 | Series Unknown | €6M | 1 | — | — | Detail |
| Feb 2, 2010 | Series B | $5.40M | 1 | — | — | Detail |
| Nov 19, 2009 | Series A | €4M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ERP Startfonds
|
— | Series Unknown |
